Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases.


Journal

Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306

Informations de publication

Date de publication:
26 07 2019
Historique:
received: 05 11 2018
accepted: 16 12 2018
pubmed: 23 2 2019
medline: 2 4 2020
entrez: 23 2 2019
Statut: ppublish

Résumé

There is only limited information on serum reference ranges of calcitonin (CT) in infants, children and adolescents. This gap hampers valid diagnostics in patients with multiple endocrine neoplasia type 2 (MEN 2) and planned prophylactic thyroidectomy. In addition, age-dependent reference ranges for CT are necessary to define a cure in medullary thyroid carcinoma (MTC). We asked whether the reference ranges for CT levels were age- and gender-dependent in the serum of a pediatric cohort. A total of 6090 serum samples of 2639 subjects of the LIFE-Child cohort aged between 1 month and 17.9 years were analyzed by the CT electrochemiluminescence immunoassay (ECLIA). Reference intervals were estimated using the LMS method. For clinical validation the serum of 28 patients (61 samples) with MEN 2 and 106 patients (136 samples) with thyroid diseases were analyzed. CT levels showed a clear age- and gender-dependence with significantly higher values in boys (p<0.01). An accelerated decline of CT levels from newborn to children at the age of 4 and 5 years was observed for both sexes. A cure for MTC was demonstrated in 71% of MEN 2 patients after thyroidectomy, whereas 5 patients remained suspicious for micrometastasis or relapse. Only 1.5% of our patients with thyroid diseases revealed increased CT levels. This is the largest study to establish novel pediatric reference ranges from the CT values of healthy subjects. It allows a precise laboratory monitoring of CT in pediatric patients with MEN 2. Thyroid diseases did not have a relevant influence on CT levels in our pediatric cohort.

Sections du résumé

BACKGROUND
There is only limited information on serum reference ranges of calcitonin (CT) in infants, children and adolescents. This gap hampers valid diagnostics in patients with multiple endocrine neoplasia type 2 (MEN 2) and planned prophylactic thyroidectomy. In addition, age-dependent reference ranges for CT are necessary to define a cure in medullary thyroid carcinoma (MTC). We asked whether the reference ranges for CT levels were age- and gender-dependent in the serum of a pediatric cohort.
METHODS
A total of 6090 serum samples of 2639 subjects of the LIFE-Child cohort aged between 1 month and 17.9 years were analyzed by the CT electrochemiluminescence immunoassay (ECLIA). Reference intervals were estimated using the LMS method. For clinical validation the serum of 28 patients (61 samples) with MEN 2 and 106 patients (136 samples) with thyroid diseases were analyzed.
RESULTS
CT levels showed a clear age- and gender-dependence with significantly higher values in boys (p<0.01). An accelerated decline of CT levels from newborn to children at the age of 4 and 5 years was observed for both sexes. A cure for MTC was demonstrated in 71% of MEN 2 patients after thyroidectomy, whereas 5 patients remained suspicious for micrometastasis or relapse. Only 1.5% of our patients with thyroid diseases revealed increased CT levels.
CONCLUSIONS
This is the largest study to establish novel pediatric reference ranges from the CT values of healthy subjects. It allows a precise laboratory monitoring of CT in pediatric patients with MEN 2. Thyroid diseases did not have a relevant influence on CT levels in our pediatric cohort.

Identifiants

pubmed: 30794525
doi: 10.1515/cclm-2018-1186
pii: /j/cclm.ahead-of-print/cclm-2018-1186/cclm-2018-1186.xml
doi:
pii:

Substances chimiques

Biomarkers 0
Calcitonin 9007-12-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1242-1250

Auteurs

Felix Eckelt (F)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital of Leipzig, Leipzig, Germany.

Mandy Vogel (M)

LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.

Mandy Geserick (M)

LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.

Toralf Kirsten (T)

LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.

Yoon Ju Bae (YJ)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital of Leipzig, Leipzig, Germany.

Ronny Baber (R)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital of Leipzig, Leipzig, Germany.
LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.

Michael Schaab (M)

MVZ Laboratory Reising-Ackermann MD and Colleagues, Leipzig, Germany.

Joachim Thiery (J)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital of Leipzig, Leipzig, Germany.

Roland Pfaeffle (R)

Hospital for Children and Adolescents, Centre for Paediatric Research, Department of Women and Child Health, University Hospital of Leipzig, Leipzig, Germany.

Friedhelm Raue (F)

Endocrine Practice, Molecular Genetic Laboratory, Heidelberg, Germany.

Wieland Kiess (W)

LIFE-Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.
Hospital for Children and Adolescents, Centre for Paediatric Research, Department of Women and Child Health, University Hospital of Leipzig, Leipzig, Germany.

Juergen Kratzsch (J)

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital of Leipzig, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH